An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Daniel S. Mytelka
Advertisement
Articles by Daniel S. Mytelka
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
